Company

GlyProVac ApS

Rocket Ship Rating

Rocket Ship Rating: 75 out of 100

Biotech & therapeutics

Business model: B2B

glyprovac.com (opens in a new tab)

Open relationship map

Claim, correct or request removal

Record updated 4 October 2026

About

Novel BEMAP TechnologyStarting with E. coli-based infections like UTIs, GlyProVac’s BEMAP platform is an engine for creating novel bacterial vaccines.

Investor VC firms in this preview

Science Ventures Denmark A/S

VC firm
Company
Partner

VC firm names are a sample from VC Catalog’s database and may be incomplete. A database connection is not a guarantee of an introduction.

GlyProVac ApS

About

Relationship map preview

Relationship map preview